

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

NCT03999229

Status	RECRUITING
Phase	Phase 1
Sponsor	James Reynolds
Enrollment	35 participants

Key Eligibility Criteria

Inclusion (4)

- Eligibility Criteria
- Hemoglobin \gt 12 g/dl
- Healthy, non-pregnant adults with no pre-existing blood disorders or disease states that impact oxygen delivery.
- a. Active blood and platelet donors will be sought as study participants since these individuals are familiar with the routines for blood withdrawal and re-infusion.

Exclusion (17)

- Individuals who are pregnant, breastfeeding, or are unwilling to avoid pregnancy during the study.
 - Individuals with an anatomic anomaly that would increase the risks associated with placement of the vascular catheters.
 - Individuals who report chronic diseases requiring medication of the heart, lungs, kidney, liver, etc or afflicted with any acute or chronic pathology that in the opinion of the screening physician makes them unsuitable for study.
 - Individuals with a recent history of antibiotic therapy (check for underlying cause).
 - Individuals unwilling to refrain from taking any phosphodiesterase 5 (PDE-5) inhibitor for at least 24 h prior to donation and/or autologous transfusion.
- ... and 12 more (see full listing online)

Locations (1 total)

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States